絞り込み

16421

広告

不安払しょく 被ばく量試算できるアプリ開発へ (NHK)

原発事故で避難している人たちのうち、帰還を考えている人などの不安を少しでも払拭(ふっしょく)しようと原子力規制委員会は、福島県内での生活パターンを踏まえて被ばく...

  1. トランプ政権1年 深刻な国際秩序の「漂流...
  2. 着物 タンスに眠らせず 京都大(キャンパ...
  3. 遺体は蓮ちゃん、DNA鑑定で断定 - 福...
  4. 物質のナノレベル解析に光 次世代放射光施...

ニュース一覧

Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials.

著者 Coppolino G , Leporini C , Rivoli L , Ursini F , di Paola ED , Cernaro V , Arturi F , Bolignano D , Russo E , De Sarro G , Andreucci M
Pharmacol Res.2017 Dec 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (26view , 0users)

Full Text Sources

Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a relatively new class of non-insulin glucose-lowering agents, belonging to the incretin family, which are able to improve glycemic control with a favorable safety profile, since they are associated with a low risk of hypoglycemia, no weight gain, and good tolerability in patients with chronic renal failure. Some experimental and clinical studies suggest that these drugs may exert significant pleiotropic effects, in particular on chronic kidney disease (CKD) progression, but data from clinical trials are still controversial. In an effort to clarify the effects of DPP-4 inhibitors (DPP-4is) on diabetes-related renal damage, we performed a narrative review of available clinical trials and other experimental studies focusing on renal effects of DPP-4is. Currently, there is no conclusive evidence proving the usefulness of this drug class for improving diabetes-related renal damage. However, our literature review suggests that DPP-4is are safe and well tolerated in type 2 diabetes mellitus (T2DM) patients with CKD. More importantly, results from the reviewed studies indicate that DPP-4 inhibitor therapy may improve two major risk factors for diabetic nephropathy, such as hyperglycemia and albuminuria, resulting in potential renal benefits beyond glycemic control. Despite several limitations, the conclusions of our review corroborate previous evidence on the potential renal benefits of DPP-4is, highlighting the urgent need of future trials adequately powered and designed on hard renal outcomes to ascertain (or contradict) the therapeutic benefit of DPP-4is in T2DM and CKD patients.
PMID: 29223646 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード